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Hepatocellular carcinoma (HCC) frequently develops in a pro-inflammatory and pro-fibrogenic
environment with hepatic stellate cells (HSCs) remodeling the extracellular matrix composition. Molecules
secreted by liver tumors contributing to HSC activation and peritumoral stromal transformation remain to
be fully identified.Herewe show that conditionedmedium fromHCCcell lines, Hep3B andHepG2, induced
primary mouse HSCs transdifferentiation, characterized by profibrotic properties and collagen
modification, with similar results seen in the human HSC cell line LX2. Moreover, tumor growth was
enhanced by coinjection ofHepG2/LX2 cells in a xenograftmurinemodel, supporting aHCC-HSC crosstalk
in liver tumor progression. Protein microarray secretome analyses revealed angiogenin as the most robust
and selective protein released byHCC compared to LX2 secretedmolecules. In fact, recombinant angiogenin
induced in vitro HSC activation requiring its nuclear translocation and rRNA transcriptional stimulation.
Moreover, angiogenin antagonism by blocking antibodies or angiogenin inhibitor neomycin decreased in
vitro HSC activation by conditioned media or recombinant angiogenin. Finally, neomycin administration
reduced tumor growth ofHepG2-LX2 cells coinjected inmice. In conclusion, angiogenin secretion byHCCs
favors tumor development by inducing HSC activation and ECM remodeling. These findings indicate that
targeting angiogenin signaling may be of potential relevance in HCC management.
T
umor microenvironment is known to modulate the progression of human cancers1. In particular, hepato-
cellular carcinoma (HCC), themost common type of liver tumor, develops in amulticellular milieu in which
parenchymal and non-parenchymal hepatic cells coexist with non-hepatic infiltrating cells, mostly inflam-
matory, providing an adequate cellular scenario that facilitates HCC progression2,3.
The communication of tumor cells with stromal cells within the extracellular matrix (ECM) paves the way for
HCC development. Therefore, targeting stromal cells or interfering with the reciprocal cross-talk between
stromal and tumor cells may stand as a critical strategy for cancer therapy1,2. In this regard, hepatic stellate cells
(HSCs) transform during chronic liver injury from a quiescent state into a myofibroblast-like phenotype, which
proliferate and migrate towards areas of necrosis and regeneration, as described in several pathological condi-
tions4,5. Besides their participation in ECM production and degradation, activated HSCs are an important source
of hepatic cytokines such as TGF-b, PDGF, HGF, CTGF, FGF, and VEGF, and recruit inflammatory cells, mono-
and polymorphonuclear leukocytes that in turn produce chemokines, including MCP-1, CCL21, RANTES,
CCR5.
Recent data point out that HSC transformation represents a crucial cell reprogramming event that shifts HSC
from a normal vitaminA-storing to an ECM-remodeling phenotype5, favoring a tumorigenicmilieu forHCC. For
instance, the amount of peritumoral activated HSCs after curative resection predict early recurrence and poor
clinical outcome in patients with HCC6. Moreover, HCC-HSC cross-talk generates a permissive proangiogenic
microenvironment, particularly by inducing VEGF-A andMMP9 expression in HSCs and increasing motility in
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hepatocytes7. However, the identification of HCC-secreted media-
tors that activate surrounding HSCs and consequently facilitate can-
cer progression remains to be fully explored.
Angiogenin was the first isolated tumor-derived protein with in
vivo angiogenic activity8 featuring a ribonuclease activity that stimu-
lates ribosomal RNA (rRNA) transcription and cell proliferation9.
Increased angiogenin serum levels have been associated with the
incidence and severity of several human tumors10–12, including
HCC13,14. Hepatocytes release angiogenin extracellularly15, which is
first taken up by a specific transporter in endothelial and cancer cells,
and then undergoes translocation to the nucleus through a phospho-
lipase C dependent mechanism16. Angiogenin direct binding to the
promoter region of ribosomal DNA induces rRNA transcription
required for ribosomal biogenesis and the action of angiogenic fac-
tors, being essential for cell growth and proliferation. Neomycin,
an aminoglycoside antibiotic, interferes with angiogenin nuclear
targeting resulting in its perinuclear sequestration17, thus blocking
angiogenin-induced cell proliferation and angiogenesis12,17,18.
Interestingly, angiogenin is upregulated by hypoxic conditions in
melanoma19 and other tumor cells20, and by inducers of acute-phase
response in human HepG2 cells21. Angiogenin has been proposed as
a putative noninvasive marker for monitoring HCC13, and increased
angiogenin expression in patients with HCC correlates with major
tumor vascularity andmortality14. However, the role that angiogenin
plays inHSC activation has not been previously addressed. Thus, our
aim was to analyze if angiogenin is secreted by HCC and to examine
the role of angiogenin in HSC activation andHCC-HSC cross-talk in
liver cancer.
Materials and Methods
Reagents. DMEM, Trypsin-EDTA, Penicillin-streptomycin, TRIzol, FBS, were from
Invitrogen (Paisley, United Kingdom). All tissue culture ware was from Nunc
(Roskilde, Denmark). Biotin Blocking System, peroxidase substrate (DAB),
peroxidase buffer, and hematoxylin were fromDAKO (Glostrup, Denmark). Aquatex
was from Merck (Darmstadt, Germany). The ABC kit was from Vecstain
(Burlingame, CA). Proteinase inhibitors were from Roche (Madrid, Spain). ECL
western blotting substrate was from Pierce (Thermo Fisher Scientific, Rockford, IL).
Neomycin and recombinant Angiogenin was from Sigma-Aldrich, and unless
otherwise stated, all other reagents were also from Sigma-Aldrich (St. Louis, MO).
Cell culture and conditioned medium preparation. Human liver tumor cell lines
Hep3B andHepG2 (European Collection of Animal Cell Cultures (ECACC)), and the
human immortalized HSCs (LX2)22,23 were routinely grown in DMEM culture
medium supplemented with 10% fetal bovine serum (FBS), and antibiotics at 37uC
and 5% CO2. For conditioned medium (CM) preparation, HepG2, Hep3B, or LX2
cells were grown until optimal confluence (80–100%). Cell monolayers were washed
three times in sterile 1x PBS and replenished with 15 mL of DMEM (serum free for
microarray assays). After 24 hours, media were removed, filtered (0.22 micron) and
stored at 220uC.
HSCs isolation and culture. Livers from wild-type male C57BL/6 mice (12215
weeks old) were perfused with collagenase and HSCs cultured as previously
described22,23. Culture purity, assessed routinely by retinoid autofluorescence at
350 nm, was.95%. Cells were cultured in DMEM supplemented with 10% FBS, and
antibiotics at 37uC and 5% CO2. Since HSCs become activated after its culture in
plastic in a time-dependent fashion, experiments to observe protein or mRNA
content were always performed with cells at the same time of culture, with previous
administration of CM, recombinant angiogenin or inhibitors for the indicated
periods of time.
Immunofluorescence. LX2 cells were grown in coverslips, rinsed with PBS, fixed in
formalin and permeabilized in saponin for 10 min. After incubation with PBS
containing 5% BSA for 1 hour, monoclonal anti-angiogenin (C-1) (sc-74528 Santa
Cruz Biotechnologies, 1:50 in PBS-BSA, 2 h, RT) was added. Later, coverslips were
incubated with Alexa Fluor 488 anti-mouse (Molecular Probes, 1:500, 1 h, RT) and
Hoechst 33258 (Sigma, 0.2 mg/ml) mounted. Confocal images and single optical
sections were collected using a Leica SP2 laser scanning confocal microscope.
RNA silencing. HepsG2 and Hep3B cells were transfected with lentiviral particles
containing expression constructs, each encoding target-specific 19–25 nt (plus
hairpin) shRNA, designed to knockdown gene expression of angiogenin (shANG,
sc-39291-V, Santa Cruz Biotechnologies) or control particles (shCTRL, sc-108080).
Hepatoma cells stably expressing shRNAs were isolated by puromycin selection.
Antibody Array. RayBioH Human Angiogenesis Antibody Array 1 and 2 (G-Series,
from RayBiotech), which allows simultaneous detection of 43 angiogenic-related
proteins (Array components in Suppl. Fig. 1), were used to assess secretion profiles in
conditioned media (CM) of HepG2, Hep3B and LX2 cells, according to
manufacturer’s instructions. Representative medium (DMEM, 10% FBS), not
exposed to cells, was used as negative control. Arrays were visualized using
ImageQuant LAS4000 software (GEHealthcare) and analyzed with ImageJ (National
Institutes of Health).
Tumor animalmodel.All animal procedures were performed according to protocols
approved by the Animal Experimentation Ethics Committee from the University of
Barcelona. For subcutaneous tumormodel,Male Swiss nudemice, 5–6week old, were
kept under pathogen-free conditions with free access to standard food and water.
HepG2 cells (2 3 106), Hep3B cells (2 3 106), LX2 cells (2 3 106) alone or in
combination HepG2/LX2 cells (2 3 106/0.4 3 106), Hep3B/LX2 cells (2 3 106/
0.4 3 106), were injected subcutaneously into the flanks of mice in 200 mL DMEM
media without FBS24,25. To analyze neomycin effect on tumor growth, three days later
mice were randomly divided into 2 experimental groups: saline (control) or
Neomycin (60 mg/Kg) were subcutaneously injected daily, as previously reported18.
Tumors were measured periodically with a vernier caliper, and the volume was
calculated as length 3 width2 30.5.
H&E and immunohistochemical staining. Livers were fixed and 7-mm sections were
routinely stained with H&E or paraffin sections (5-mm) were prepared following
standard procedures22,23,26. The antibodies used were rat mAb anti-CD34 (1:50
dilution, ab8158, Abcam), goat polyclonal anti-antiogenin (C1) (1:200, sc-74528,
Santa Cruz Biotechnology), mAb anti-PCNA antibody (PC10) (1:200 dilution, sc-56,
Santa Cruz Biotechnology) and anti-CD34 (1:100 dilution, sc-18917, Santa Cruz
Biotechnology). The slices were examined with a Zeiss Axioplan microscope
equipped with a Nikon DXM1200F digital camera. PCNA index was quantified in
four randomly selected fields from each animal, and CD34 positive areas analyzed
using ImageJ software.
SDS-PAGE and immunoblot analysis. Cell lysates were prepared in RIPA buffer
plus proteinase inhibitors. Samples containing 10 to 30 mg were separated by 8–10%
SDS-PAGE. Proteins were transferred to nitrocellulose membranes, blocked in 8%
nonfat milk for 1 h at room temperature, and incubated overnight at 4uC with
primary antibodies mAb anti-a-SMA (A2547, Sigma-Aldrich), mAb anti-
Angiogenin (sc-74528, Santa Cruz Biotechnologies), mAb anti-PCNA (sc-56, Santa
Cruz Biotechnologies), rabbit polyclonal anti-cathepsin B (06-480, Millipore), rabbit
polyclonal anti-MMP9 (sc-6841-R, Santa Cruz Biotechnologies), mAb anti-b-actin
(A1978, Sigma-Aldrich) and developed with ECL-peroxidase system.
RNA isolation and real time RT-PCR. Total RNA was isolated with TRIzol reagent.
Real-time RT-PCR was performed with SensiFAST SYBR One-Step Kit (Bioline.
Ecogen, Barcelona, Spain) following the manufacturer’s instructions22,23,26. The
primers sequences used were: human a-SMA, Fw 59-TTCAGCTTCCCTGAACA-
CCAC-39, Rv 59-CAGAGCCATTGTCACACACC -39 (GenBank# NM_001613);
human TGF-b, Fw 59-GAGCCTGAGGCCGACTACTA-39 and Rv 59-CGGAGCT-
CTGATGTGTTGAA-39 (GenBank# NM_000660); human b-actin, Fw: 59-GGACT-
TCGAGCAAGAGATGG-39and Rv: 59-AGGAAGGAAGGCTGGAAGAG -39
(GenBank# NM_001101), human RPII, Fw: 59-GACACAGGACCACTCATGA-
AGT-39 and Rv: 59-GTGCGGCTGCTTCCATAAG-39 (GenBank # NM_000937);
human 45S, Fw: 59-CTGACACGCTGTCCTCTGG-39 and Rv: 59- GGTCACC-
GGTAGGCCAGA-39 (GenBank# NM_007742); mouse a-SMA, Fw 59-ACTAC-
TGCCGAGCGTGAGAT-39 and Rv 59-AAGGTAGACAGCGAAGCCAA -39
(GenBank# NM_007392); mouse TGF-b, Fw 59-GTCAGACATTCGGGAAGCAG-
39 and Rv 59- GCGTATCAGTGGGGGTCA-39 (GenBank# NM_011577); mouse
Col1A1, Fw: 59-ACTTCACTTCCTGCCTCAG-39 and Rv: 59-TGACTCAGGCTCT-
TGAGGGT-39 (GenBank# NM_007742); mouse b-actin, Fw: 59-GACGGCCAGGT-
CATCACTAT-39and Rv: 59-CGGATGTCAACGTCACACTT -39 (GenBank#
NM_007393).
Human serum samples. Patients (adult males) gave written consent in accordance
with the Declaration of Helsinki, and the protocol, approved by ethical committees
from the Hospital Clinic, followed ethical guidelines on handling of human samples.
Additional data of patients is provided in Suppl. Fig. 2.
Statistical analyses. All images display representative data from at least 3
independent observations, unless indicated. Results are expressed as mean 6 SEM
and the statistical significance of differences (p value less than 0.05) was performed
using the unpaired, non-parametric Student’s t test, unless indicated.
Results
Conditioned medium from hepatoma cells transforms primary
murine HSCs in vitro. 7-day old primary mouse HSCs were
collected after being exposed for up to 5 days to conditioned medium
from human cell lines HepG2 (CM-HepG2) or Hep3B (CM-Hep3B) to
verify the capacity of hepatoma-derived CM to induce HSC activation27.
Compared to 7-day old non-treated HSCs, exposure to CM-HepG2
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induced significant changes in a-SMA expression (Fig. 1A), while
exposure to CM-Hep3B augmented also a-SMA expression but to
a lesser extent (Fig. 1B). In fact, changes in HSC morphology,
indicative of HSC transformation, were observed in HSCs as soon
as 2 days after exposure to CM-HepG2 (Fig. 1D). However, addition
of medium from LX2 cells (CM-LX2), a cell line of human activated
stellate cells, induced no visible changes in HSC appearance (Fig. 1D)
or a-SMA expression (Fig. 1C). Moreover, COL1A1 mRNA levels
displayed increased expression in HSCs within hours of CM-HepG2
exposure (Fig. 1E), showing significant increases as soon as 4 h after
CM addition, before the overexpression of other profibrogenic genes
such as TGF-b. In addition, enhanced mRNA expression of HSC-
activated genes, such as TGF-b and COL1A1, was exhibited for
several days (Fig. 1F).
HCC-secretome further activates LX2 cells in vitro andHSC-HCC
co-implantation promotes tumor growth. To verify if hepatoma-
derived medium could also potentiate human HSC cell activation,
LX2 cells were exposed to conditioned medium from HepG2
and Hep3B. Although LX2 is a clonal myofibroblastic HSC cell
line, frequently used as a surrogate of human activated HSCs,
both cell lines further increased LX2 activation monitored by
a-SMA (Fig. 2A), supporting the pro-fibrogenic capacity of
HCC secretome. Moreover, either HepG2 (Fig. 2B) or Hep3B
(Fig. 2C) enhanced the mRNA expression of genes induced
during HSC transformation, such as TGFb, COL1A1 or a-SMA.
Of note, CM from HepG2 cells induced a more potent stimu-
lation, maybe indicating a major content of HSC-activating
molecules.
Once observed the ability of liver tumor cells to induce HSC
activation, we wanted to verify if HCC-HSC association may pro-
mote hepatocarcinoma tumor growth in vivo. To do so, HepG2, LX2
or a combination of both cells (HepG2/LX2, ratio 5:1) were injected
in the flanks of nude mice. Injection of LX2 cells alone did not
generate any tumor, as previously observed with activated HSCs28.
However, LX2 cells injected in combination with HepG2 greatly
enhanced subcutaneous tumor growth over time, compared to
HepG2 cells alone (Fig 2D). Similarly, Hep3B/LX2-derived tumors
also exhibited accelerated cancer progression, compared to Hep3B
tumors (Fig. 2E).
Angiogenin is secreted by HCC cells. Since HepG2 and Hep3B cell
lines were able to activate HSCs, while another human liver cell line
such as LX2 did not, we analyzed a panel of cytokines, chemokines,
growth factors and angiogenic factors in an attempt to identify
activating molecules in the differential protein profile secreted by
HCC and LX2 cells using commercial protein microarrays (Suppl.
Fig. 1). In comparing the protein expression of HepG2 and Hep3B
with respect to LX2 cells (Fig. 3), we observed that out of the 43 target
proteins, angiogenin exhibited a marked increased expression (up
to 10–20 fold) in HCC cells, being particularly high in HepG2
secretome (Fig 2B). Other proteins, such as vascular endothelial
growth factor (VEGF) and epidermal growth factor (EGF),
previously described as HSC activators, were clearly enhanced
(Fig. 2B), while moderate increases expression of endostatin and
I-TAC (CXCL11), in Hep3B secretome, were also detected (Fig. 2D).
On the other hand, enhanced extracellular expression of MCP-1, IL-6
(Fig 1B), uPAR, MMP1 and MMP9 (Fig. 2D) were observed in LX2
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cells compared to hepatoma cell lines, reflecting the endogenous
activation of LX2 cells. Since the role of angiogenin in HSC biology
has not been previously addressed, we next focused on the impact and
mechanisms underlying the HSC activation by angiogenin.
Recombinant angiogenin inducesHSC activation and its elimination
from CM-HepG2 reduces HSC transformation. Increased serum
angiogenin levels have been detected in patients with different types
of cancer, and in particular, poor HCC prognosis correlates with
angiogenin expression14. However, no evidence of angiogenin effect
on HSC pathophysiology has been previously reported. To address
whether angiogenin may reproduce the effect of HCC-derived CM
on HSC activation, primary HSCs were exposed to recombinant
angiogenin (rANG) to monitor fibrogenic markers. Similar to CM-
HepG2-treated HSC cells, angiogenin-treated HSCs displayed higher
a-SMA proteins levels than untreated cells (Fig. 4A). Moreover, other
proteins that participate in ECM remodeling, such as cathepsin B (CtsB)
or MMP9, or indicative of HSC proliferation, such as PCNA, were also
elevated by rANG administration (Fig. 4A).
To evaluate if reduction of angiogenin expression in HepG2 med-
iummodulates HSC activation by CM-HepG2, we generated HepG2
cells stably expressing control or anti-angiogenin vector coding for
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shRNA against angiogenin. Although, RNA silencing was effective in
decreasing angiogenin mRNA levels and protein expression in
HepG2-released medium (Fig. 4B), this reduction was insufficient
to decreaseHSC activation (Fig. 4C) byCM.Moreover, no changes in
tumor incidence or tumor growth were detected between groups
when HepG2 cells stably transfected with shANG or shCTRL were
coinjected with LX2 cells in nude mice (data not shown).
Since RNA interfering did not completely eliminate angiogenin
expression, we examined an alternative fashion to deplete angiogenin
content using an anti-angiogenin antibody, that, as seen, quantita-
tively immunoprecipitated angiogenin from CM-HepG2 medium
(Fig. 4D). Angiogenin depletion significantly reduced HSC activa-
tion induced by CM-HepG2 medium (Fig. 4D) suggesting that
complete elimination of angiogenin is required to abolish its HSC
activating capacity.
Neomycin blocks angiogenin nuclear translocation and reduces
angiogenin-induced HSC transformation. Previous studies have
reported that the uptake of angiogenin and its nuclear translocation
are required for translational changes and ribosomal biogenesis.
Moreover, angiogenin-induced reprogramming may be antagonized
by genetic knockdown or by interfering with its nuclear location by
the aminoglycoside antibiotic neomycin12,17,18. To verify if angiogenin
undergoes a distribution change in activated HSCs, and to validate
the potential use of neomycin as an inhibitor of angiogenin, we
followed angiogenin distribution in LX2 cells by confocal micro-
scopy (Fig. 5A). After administration of rANG, both nuclear and
perinuclear distribution of angiogenin was detected in LX2 cells.
Interestingly, neomycin incubation antagonized angiogenin nuclear
trafficking, resulting in increased perinuclear location (Fig. 5A),
blocked nuclear deposition that precluded interaction of DNA
with angiogenin, as indicated by the lack of colocalization with the
DNA-binding dye Hoechst 33258. To evaluate if neomycin blockage
of angiogenin signaling in HSC is translated in a direct effect on
proliferative and profibrotic markers we analyzed neomycin effect
on HSC-treated with conditioned medium and with rANG. In
accordance with a role of angiogenin in HSC transformation,
neomycin reduced the phenotypic changes induced by CM-HepG2
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in primary HSCs as indicated by a-SMA, MMP9 and PCNA
expression (Fig. 5B). Of note, neomycin decreased HSC activation
by rANG, measured by a-SMA protein level (Fig. 5C).
Angiogenin levels do not increase in patients with ALD. HSC
activation is a hallmark of progressive fibrosis during hepatic
deterioration in liver diseases. Our data indicates that angiogenin
is an inducer of HSC activation in vitro, however, a relevant role of
angiogenin in the HSC activation during liver fibrosis has not been
previously proposed. To evaluate the contribution of angiogenin on
HSC activation during chronic liver injury, we analyzed the levels of
angiogenin in serum samples from individuals with different stages
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of alcoholic liver disease (ALD). No differences in angiogenin serum
content were observed in alcoholic patients with fibrosis or
compensated cirrhosis compared to control individuals (Fig. 6). Of
note, cirrhotic decompensated patients displayed an important
reduction of angiogenin levels, in line with previous results14.
Therefore, although angiogenin secreted by hepatoma cells, might
modify liver cancer microenvironment via HSC-induced matrix
remodeling, and angiogenin serum levels have been found increase
in HCC patients as the tumor vascularity increase14, angiogenin
concentration is not a reliable pre-neoplasic marker for liver
cancer development, at least in a background of ALD. Therefore,
angiogenin induced by hepatoma cells may induce further
activation of already active HSCs, as observed in LX2 cells,
contributing to HCC development, but without playing a role in
initial HSC activation during liver fibrosis.
Neomycin administration markedly reduces HepG2/LX2 in vivo
tumor growth. To explore the potential therapeutic relevance of
neomycin in HCC, we followed tumor growth in the xenograft
model with or without in vivo treatment with neomycin. Nude
mice were treated daily with neomycin or saline subcutaneously to
follow the growth of tumor growth in xenografts injected with
HepG2 cells with or without LX2 cells. While no significant
changes were observed in tumor multiplicity between groups (7
out of 10 in saline group, vs. 6 out of 10 in neomycin group),
tumor growth determined by tumor volume (Fig. 7A) was clearly
lower in neomycin-treated mice. Of note, tumors from neomycin-
treated animals emerged slower, and tumor development was
significantly diminished in equal size tumors (e.g. estimated
doubling time for 50 mm3 tumors was 6.0 6 1.2 days in saline-
treated animals vs. 10.1 6 2.1 in neomycin treated mice). In fact,
HCC proliferation was reduced in neomycin-treated animals
(Fig. 7B), as quantified in tumor slides by PCNA index
measurement (Fig. 7C), while a reduction in tumor vascularization
was determined by CD34 immunohistochemistry (Fig. 7B), and the
positive areas quantified (Fig. 7D).
Consistent with reduced HSC activation, tumors from neomycin-
treated mice displayed significant decreased TGF-b mRNA levels
(Fig. 7E). Since nuclear angiogenin participates in rRNA transcrip-
tion29, a rate-limiting step in ribosome biogenesis, which can be
monitored by measurement of the steady-state level of 45S rRNA,
we analyzed 45S rRNA expression. Neomycin treatment reduced
significantly 45S rRNA levels, without detectable changes in RNA
polymerase II (RPII) levels (Fig. 7F), discarding nonspecific effects of
neomycin on RNA synthesis. In line with lower ribosomal activity,
angiogenin nuclear location was almost absent in slides from neo-
mycin-treated tumor-bearing mice (Fig. 7B) resulting in reduced cell
proliferation, as indicated by PCNA (Fig. 7C) and tumor growth
(Fig. 7A).
To address whether neomycin antagonizes HCC growth by
directly regulating tumor cell proliferation, HepG2 cells were treated
with neomycin in vitro. As seen, neomycin treatment with did not
cause any decrease in HepG2 cell growth, even at high doses (2 mM)
for up to a week (Supplemental Fig. 3), implying that the promoting
effect of angiogenin in tumor growth is not due to its direct effect on
HepG2 proliferation but most probably by favoring the micro-
environment in which HCC develops. Moreover, other liver cancer
cell lines such as Hep3B (human), H35 (rat) or Hep1c1c7 (mouse)
were also treated with neomycin and no effects on cell proliferation
were detected (data not shown). In addition, mice bearing subcuta-
neously HepG2 cells alone, did not displayed significant changes in
tumor growth after neomycin administration (data not shown), sug-
gesting that angiogenin signaling participates in the promotion of
HepG2 tumor development induced by LX2 cells.
Discussion
HCC onset and progression is a complex process that requires multi-
factorial players2,3. Liver injury associated with inflammation and
fibrosis precedes the occurrence of HCC, suggesting that HSC activa-
tion orchestrates a favorable scenario for HCC growth. Previous
observations using a co-culture approach between HCC cells and
primary HSC have suggested that activated HSCs play a supportive
role in tumor progression by stimulating pro-angiogenic events and
promoting tumor survival27,28. The role of disease-specific proteins in
the cell secretome is crucial in regulating cell-to-cell and cell-to-
extracellular matrix interactions, and the identification of specific
molecules present in conditioned media from cell lines is an inter-
esting approach for biomedical research29. Comparing the protein
content of two well-studied hepatoma cell lines (HepG2 and Hep3B)
to the secretome composition of a human myofibroblastic cell line
(LX2) has obvious limitations, but may provide hints of molecules
involved in the cellular cross-talk during liver cancer implantation
and progression. By doing so, our data identify angiogenin as novel
player in a positive loop by which HCC mediates HSC activation,
which accelerates and amplifies HCC development (Figure 8). Our
findings indicate that HCC-mediated secretion of angiogenin
induces, or even aggravate, HSC activation promoting a phenotype
with ECM remodeling activity. On the contrary, angiogenin ant-
agonism may affect cancer microenvironment, reducing vessel
formation and slowing down tumor growth in in vivo HCC models.
Consistent with previous observations that increased angiogenin
levels in cancer stroma contribute to ECM degradation and promote
tumor cell invasion10,17, we provide evidence that angiogenin is a
critical HCC-derived mediator that stimulates HSC transdifferentia-
tion. However, despite serum angiogenin levels increase in HCC,
angiogenin is not expected to be a preneoplasic marker of HCC since
patients with developed hepatic fibrosis or cirrhosis show levels sim-
ilar to control subjects. In fact, a lower angiogenin levels is presented
by ALD patients with decompensated cirrhosis, in which most of
their HSCs are expected to be activated, suggesting that angiogenin is
not playing a relevant role in the initial HSC activation that occurs
during liver fibrosis.
Interestingly, increased expression of angiogenin in tumor cells
has been observed under hypoxic conditions, as in melanoma cells,
and after exposure of HepG2 to inflammatory cytokines including
IL-620,21. Since low oxygen tension profile and inflammatory micro-
environment are consistent features of HCC development, further
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Figure 6 | Angiogenin serum levels are not increased in ALD.Angiogenin
serum levels were measured in control individuals (n 5 5) and patients
with liver pathologies: ALD, alcoholic liver disease (n5 9, age: 48.16 3.8),
HC, hepatic cirrhosis (n 5 7, age: 58.1 6 2.4, MELD: 10.3 6 1.6), and
HCD, hepatic cirrhosis decompensated (n5 9 age: 51.36 2.2,MELD: 14.3
6 1.8). Additional data of patients is provided in Suppl. Fig. 2.
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enhanced angiogenin levels may be expected in peritumoral areas,
inducing HSC phenotypic transformation. In addition, angiogenin
plays a prominent role in endothelial cell proliferation induced by
other tumor secreted proteins, including VEGF, acidic and basic
fibroblast growth factors, and EGF, which requires its nuclear traf-
ficking to exert its ribonuclease activity30. Moreover, angiogenin con-
trol of tumor vasculature via hypoxia inducible factor 1 and VEGF has
been described in tumor angiogenesis through a NF-kB-dependent
PDH2-regulated mechanism31. Therefore, angiogenin directly or via
potentiation of other angiogenic factors, stands as a critical player in
tumor growth during cancer progression.
Angiogenin is mainly produced by the liver15 and exhibits a high
concentration in plasma (250–350 ng/mL) and fast turnover rate
with a half-life of 2 h, which is a limitation to the use of anti-angio-
genin antibodies or reducing its expression by siRNA approach10,18,32.
Consequently, although our findings indicate blockage of angiogenin
signaling as feasible strategy to prevent HCC progression and inva-
siveness, non-advisable large amount of angiogenin antagonists
would be needed to neutralize its circulating levels. Fortunately, neo-
mycin, an aminoglycoside antibiotic, has been reported to block
nuclear translocation of angiogenin in several tumor models in athy-
micmice, independently of its antibiotic capacity17. Since angiogenin
biological activity, mediated by rRNA transcription, requires its pres-
ence in the nucleus, preventing angiogenin nuclear translocation by
neomycin does offers an alternative approach to inhibit its action,
avoiding potential problems caused by its high blood concentration.
Our data indicates that neomycin, that has been used for years in
clinical practice as well as its derivatives such as neamine17,18, reduces
tumor growth by a direct effect in tumor microvasculature but not
directly in HCC proliferation, since we have failed to detect changes
after neomycin administration in in vitro growth of different hepa-
toma cells, in contrast to a previous observation with another cell
line33. Furthermore, alterations in angiogenin serum levels has been
described among other clinical settings34–37, in human pathologies
such as type 1 diabetes in young patients36 or inflammatory bowel
disease37 in which liver fibrosis may emerge as an unwanted
complication.
Hopefully, targeting angiogenin with small-molecule inhibitors
will be soon a treatment approach, in special if angiogenin role is
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Figure 7 | Neomycin administration reduces HCC/HSC tumor growth by blocking angiogenin nuclear translocation and HCC development.
A, measurement of tumors from nudemice subcutaneously injected with HepG2/LX2 cells and treated intraperitonealy with saline or neomycin for eight
weeks. B, Representative images of tumor cell proliferation by PCNA detection (403), angiogenin levels (803) and CD34 (403) were visualized in
tumor samples frommice treated with neomycin or saline. C, Quantification of PCNA positive cells in tumor slides.D, Quantification of CD34 positive
areas in tumor slides. E, mRNA quantification of a-SMA and TGF-b in tumors, using b-actin as control. (n $ 6). *, p # 0.05, neomycin vs.
saline-injected animals. F, RNA quantification of RNA polymerase II (RPII) and 45S ribosomal RNA in tumors, as above.
Figure 8 | Schematic representation of angiogenin role in HCC/HSC
crosstalk. Angiogenin secreted from hepatoma cells is an inducer of HSC
transformation by changing numerous proteins involved in ECM
remodeling. Among them, specific fibrillar components such as collagen,
type I, alpha 1, encoded by the COL1A1 gene, are induced, as well as
abnormal expression of enzymes that degrade type IV and V collagens and
other extracellular matrix proteins, such us MMP9, tissue inhibitors of
metalloproteinases (TIMP) or cysteine proteinases such as cathepsin B.
Consequently, physiologic ECM formation is altered due to HSC
induction, providing a profibrogenic environment that facilitates tumor
growth. In summary, liver tumor promotes its own development via
angiogenin-dependent HSC activation, and antagonism of angiogenin
signaling, as neomycin does, may be an interesting approach to halter liver
cancer progression.
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revealed for different human neoplasias. For instance, N65828, an
inhibitor of the ribonucleolytic activity of human angiogenin, has
been recently reported to diminish xenograft tumoral growth of T24
bladder carcinoma andHeLa cervical adenocarcinoma cells, through
the inhibition of angiogenesis38. Unfortunately, Ki of N65828 toward
ANG is 81 mmol/L, a value considered not good enough for drug
development12. Before more specific inhibitors are designed and pre-
clinical analysis performed, available medicines with known angio-
genin-capability, such as neomycin or neamine, are starting to be
tested for specific tumors11,12,18,39,40. In line with this approach, ther-
apies in liver cancer must take into account not only the altered
pathways in HCCs but also how the inhibition of tumor-engaged
cascades might affect the surrounding stroma, and particularly
HSCs41. It is know that HSC activation during fibrogenesis provides
a natural landscape where incipient HCC cells are stimulated. Now,
our data identify a new role in liver tumors for angiogenin by par-
ticipating in HCC/HSC crosstalk, and provide compelling evidence
pointing to angiogenin targeting as a potential novel strategy for
HCC management.
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